Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Thau

Pulmonary Disease Westport, CT Medical Doctor

NPI 1750312955 CMS profile 170458

1505 Post Rd E Ste 100, Westport, CT 06880

Open in the dashboard

General payments

$5,793

143 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Thau of Westport, CT is reported in the CMS Open Payments database as having received $5,793 across 143 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,021 53
2024 General $1,125 44
2023 General $336 15
2022 General $495 10
2021 General $1,410 13
2020 General $1,308 6
2019 General $97 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Thau
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Steven Thau were reported at $1,021. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Steven Thau Pulmonary Disease median Middle half National median
2019 $97 $377 $109–$1,340 $163
2020 $1,308 $230 $56–$907 $114
2021 $1,410 $269 $68–$1,072 $132
2022 $495 $390 $100–$1,457 $149
2023 $336 $419 $114–$1,659 $160
2024 $1,125 $476 $123–$1,818 $164
2025 $1,021 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Phadia US Inc. $1,250 1 payment
  2. AstraZeneca Pharmaceuticals LP $892 25 payments
  3. Olympus Corporation of the Americas $808 5 payments
  4. GlaxoSmithKline, LLC. $529 62 payments
  5. Midmark Corporation $500 1 payment
  6. Genzyme Corporation $368 8 payments
  7. Jazz Pharmaceuticals Inc. $317 3 payments
  8. United Therapeutics Corporation $305 8 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $152 2 payments
  10. Mylan Specialty L.P. $106 1 payment
  11. Other $565 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,883 129 payments
  2. Honoraria $1,250 1 payment
  3. Travel and Lodging $753 3 payments
  4. Consulting Fee $650 2 payments
  5. Education $257 8 payments
Products named General payments · program years 2019–2025
  1. ImmunoCAP $1,250 1 payment
  2. Olympus Capital Accessories $808 5 payments
  3. Olympus Respiratory Accessories $808 5 payments
  4. Olympus Bronchoscopes $808 5 payments
  5. TEZSPIRE $496 19 payments
  6. DUPIXENT $447 9 payments
  7. NUCALA $361 47 payments
  8. XYREM $317 3 payments
  9. FASENRA $256 4 payments
  10. XYWAV $150 1 payment
  11. Other $1,391 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

788

Median for Pulmonary Disease: 936

Drug cost

$639,505

Median for Pulmonary Disease: $487,987

Branded share of claims

83.6%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xywav Sodium,calcium,mag,pot Oxybate Brand 11 $223,841
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 202 $162,600
Nucala Mepolizumab Brand 13 $55,697
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 74 $40,561
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 73 $35,356
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 35 $33,698
Spiriva Respimat Tiotropium Bromide Brand 52 $29,007
Breo Ellipta Fluticasone/Vilanterol Brand 42 $23,461
Incruse Ellipta Umeclidinium Bromide Brand 31 $13,847
Belsomra Suvorexant Brand 21 $9,186

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$52,546

Medicare's payments for the services billed

Medicare patients

230

Average age 75

Services billed

817

125 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
COPD 47%
Ischemic heart disease 32%
Cancer 28%
Atrial fibrillation 27%
Diabetes 24%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $275
  • Amgen Inc. $13
$288 — —
DUPIXENT
  • GENZYME CORPORATION $172
$172 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $158
$158 — —
TAGRISSO
  • AstraZeneca Pharmaceuticals LP $125
$125 — —
YUPELRI
  • Mylan Specialty L.P. $106
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

143 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record